Persistence of cefotetan on red blood cells
dc.contributor.author | Davenport, Robertson D. | en_US |
dc.contributor.author | Judd, W. John | en_US |
dc.contributor.author | Dake, Louann R. | en_US |
dc.date.accessioned | 2010-06-01T19:10:30Z | |
dc.date.available | 2010-06-01T19:10:30Z | |
dc.date.issued | 2004-06 | en_US |
dc.identifier.citation | Davenport, Robertson D.; Judd, W. John; Dake, Louann R. (2004). "Persistence of cefotetan on red blood cells." Transfusion 44(6): 849-852. <http://hdl.handle.net/2027.42/72360> | en_US |
dc.identifier.issn | 0041-1132 | en_US |
dc.identifier.issn | 1537-2995 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72360 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15157250&dopt=citation | en_US |
dc.description.abstract | Cefotetan can cause severe immune hemolytic anemia that may persist long after the drug is discontinued. To study the binding of cefotetan to RBCs, patients who received cefotetan were followed and tested for the presence of antibody to cefotetan. STUDY DESIGN AND METHODS: Patients receiving cefotetan were identified from pharmacy and nursing records. Blood samples obtained for routine hematology tests were analyzed. Cefotetan binding to patients’ RBCs was tested using a previously characterized high-titer anticefotetan serum by gel technique. To determine the minimum amount of drug necessary for binding to occur, RBCs were incubated with serial dilutions of cefotetan at pH 7.4. RESULTS: Sixty patients receiving 1 to 25 g IV (median, 2 g) of cefotetan were followed for 1 to 123 days (median, 18 days). All were initially positive, for cefotetan on RBCs. Positivity persisted for up to 98 days after the last dose of drug. Fifteen patients became negative during follow-up. The first negative sample occurred at Day 30 to 123. Using the midpoint between the last positive and first negative to estimate of the duration of positivity, we estimate that cefotetan remains RBC-bound for 16.5 to 92 days (median, 67.5 days). During the follow-up period, five patients developed anticefotetan detectable in the serum. Twenty patients receiving other cephalosporin antibiotics showed no specific reactivity of their RBCs with anticefotetan. In vitro studies showed a minimum necessary drug concentration of 1 µmol/L at physiologic pH, which was not significantly altered by RBC pretreatment with ficin, sialydase, or DTT. CONCLUSIONS: Cefotetan is tightly bound to RBCs after intravenous administration and remains detectable for weeks after the last dose. Antibodies to cefotetan may occur in about 8 percent of patients receiving the drug. The minimum necessary concentration for RBC binding is low compared to an estimated plasma concentration of 240 µmol/L from a single IV dose of 1 g. | en_US |
dc.format.extent | 82471 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | 2004 American Association of Blood Banks | en_US |
dc.title | Persistence of cefotetan on red blood cells | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | From The University of Michigan Medical School, Ann Arbor, Michigan. | en_US |
dc.identifier.pmid | 15157250 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72360/1/j.1537-2995.2004.03360.x.pdf | |
dc.identifier.doi | 10.1111/j.1537-2995.2004.03360.x | en_US |
dc.identifier.source | Transfusion | en_US |
dc.identifier.citedreference | 1. Arndt PA, Leger RM, Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion 1999;39:1239-46. | en_US |
dc.identifier.citedreference | 2. Viraraghavan R, Chakravarty AG, Soreth J. Cefotetan-induced haemolytic anaemia: a review of 85 cases. Adv Drug React Roxicol Rev 2002;21:101-7. | en_US |
dc.identifier.citedreference | 3. Garratty G, Leger RM, Arndt PA. Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynec 1999;181:103-4. | en_US |
dc.identifier.citedreference | 4. Ray EK, Warkentin TE, O’Hoski PL, Gregor P. Delayed onset of life-threatening immune hemolysis after perioperative antimicrobial prophylaxis with cefotetan. Can J Surg 2000;43:461-2. | en_US |
dc.identifier.citedreference | 5. Martin C, Thomachot L, Albanses J. Clinical pharmaco-kinetics of cefotetan. Clin Pharmacokinet 1994;26: 248-58. | en_US |
dc.identifier.citedreference | 6. Judd WJ. Methods in immunohematology. 2nd ed. Durham, NC: Montgomery Scientific, 1994. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.